Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
23.05. | On the comeback trail, GSK's Blenrep scores thumbs up from Europe's CHMP | ||
23.05. | After Keytruda combo win, Gilead's Trodelvy meets the mark in solo breast cancer trial | ||
22.05. | ASCO: Roche details Itovebi's survival benefit in certain breast cancers, further backing blockbuster plan | ||
22.05. | ASCO: Roche, Jazz's Zepzelca small cell lung cancer win leaves room for improvement | ||
22.05. | CDMO Samsung Biologics telegraphs spinoff of biosim unit | ||
22.05. | Novo offers Wegovy discount for new patients, launches new ad campaign as time runs out for compounders | ||
22.05. | AstraZeneca, Merck duke it out at the top of oncologists' pharma perception ranking | ||
22.05. | FDA advisors unanimously snub Pfizer's Talzenna in broader prostate cancer population | ||
22.05. | CDMO Bora Biologics expands operations in San Diego in wake of acquisition by Tanvex | ||
21.05. | CSL Behring's first commercial shows Hizentra erasing germ concerns for primary immunodeficiency patients | ||
21.05. | After WHO loses its top donor in US, Novo Nordisk Foundation and China step up with large contributions | ||
21.05. | Pfizer reminds UK healthcare workers that LGBTIQ+ patients are 'More Than Cancer' in new campaign | ||
21.05. | Supernus casts Busy Philipps as 'Ms. Represented' in Qelbree campaign targeting women with ADHD | ||
21.05. | Thermo Fisher, Mirai Bio link up to advance and produce gene therapies | ||
21.05. | SK defeats Pfizer in Korean patent feud, opening new lines of business for pneumococcal vaccine | ||
21.05. | J&J's Darzalex wins FDA advisers' backing as potential first treatment for smoldering myeloma | ||
20.05. | FDA lays out stricter COVID vaccine policy in pivot from 'one-size-fits-all' approach | ||
20.05. | Roche's Columvi expansion bid in danger as FDA's Makary, Pazdur push for more US enrollment in cancer trials | ||
20.05. | SK Life Science starts TV ad campaign to drive patients to seizure drug Xcopri | ||
20.05. | Doctors want more educational, financial info from pharmas: report | ||
20.05. | All branded drugs not facing generic, biosimilar competition must abide by MFN order in 'all markets,' HHS tells pharma | ||
19.05. | ViiV Healthcare retakes 1st place in pharma reputation ranking among US patient groups | ||
19.05. | For Eisai and Biogen's Leqembi, first FDA-approved Alzheimer's blood test will take time to boost launch: analyst | ||
19.05. | Eisai mounts targeted TV ad push to raise awareness of Leqembi | ||
19.05. | AstraZeneca's Airsupra cuts risk of severe exacerbations by 47% in patients with milder asthma |